Trial Profile
Pembrolizumab for relapsed/refractory Hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2017 New trial record
- 01 Apr 2017 Results published in the Annals of Hematology